Bladder cancer (BCa) is the tenth most commonly diagnosed malignant cancer worldwide. Although adjuvant chemotherapy following radical cystectomy is a common therapy for muscle invasive bladder cancer patients, no applicable biomarkers exist to predict which patients will benefit from chemotherapy.
Background: Primary small cell carcinoma of the kidney (PSCCK) is exceedingly rare and data on disease characteristics and outcomes are sparse. This study examines a nationally-representative cancer registry to better characterize PSCCK.
To compare prostate specific membrane antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) and computed tomography (CT) alone for the detection of biochemical recurrence of prostate cancer (PCa) and effect on treatment.
To measure intra-fraction displacement (IFD) in post-prostatectomy patients treated with anisotropic margins and daily soft tissue matching. Pre-treatment cone beam computed tomography (CBCT) scans were acquired daily and post-treatment CBCTs for the first week then weekly on 46 patients.
To investigate the effects of a supported home-based progressive resistance exercise training (RET) programme on indices of cardiovascular health, muscular strength and health-related quality of life (HR-QoL) in prostate cancer (PCa) patients after treatment with robot-assisted radical prostatectomy (RARP).
Systematic review for the treatment of high-risk prostate cancer (HR-PCa, D’Amico classification risk system) with external body radiation therapy (EBRT)+brachytherapy-boost (BT-boost) or with EBRT+stereotactic body RT-boost (SBRT-boost).
To evaluate the impact of upper tract urothelial carcinoma (UTUC) on BCG response and progression in patients with non-muscle invasive bladder cancer (NMIBC). We performed an IRB approved review of patients with NMIBC treated with adequate intravesical BCG, as defined by the US FDA, at our institution between 2000 and 2018.
San Francisco, CA (UroToday.com) — Telix Pharmaceuticals Limited announces that the first patients have been dosed in the Phase III ZIRCON1 (NCT03849118) clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in the United States.
The overall recurrence rate for patients with kidney stones is high, classically estimated at 30-50% at 10 years. However, the rate of recurrence for individuals varies. A patient at higher risk of recurrence may benefit more from preventative dietary and pharmacologic interventions. Conversely, a patient at a lower risk of recurrence might be unnecessarily subjected […]
Background: Prostate cancer in black men is associated with poorer outcomes than their white counterparts. However, most studies reporting this disparity were conducted in localized prostate cancer and primarily in the United States. Methods: Data regarding prostate cancer incidence and mortality for East London between 2008 and 2010 were obtained from the UK National Disease Registration Service. […]
